MIST - Milestone Pharma reports etripamil data in late-stage paroxysmal supraventricular tachycardia study

Milestone Pharmaceuticals (MIST) announces the data related to key secondary endpoints from its Phase 3 NODE-301 trial of etripamil nasal spray, an investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia ((PSVT)). The data were presented at the American College of Cardiology's 70th Annual Scientific Session (ACC.21).PSVT is a rapid heart rate condition characterized by intermittent episodes of supraventricular tachycardia ((SVT)) that start and stop suddenly and without warningThe NODE-301 trial enrolling 431 patients, was an event-driven Phase 3 efficacy trial of etripamil vs. placebo for terminating SVT episodes in the at-home setting. Data presented at ACC.21 build on previous results from the NODE-301 trial that showed statistically significant improvements in favor of etripamil over placebo in the important secondary endpoint of patient reported treatment satisfaction.Treatment effectiveness (p=0.001) and global satisfaction (p=0.007) scores were greater in patients treated with etripamil than with placebo.Etripamil also had higher scores than placebo related to relief of specific symptoms associated

For further details see:

Milestone Pharma reports etripamil data in late-stage paroxysmal supraventricular tachycardia study